Dr. Nunnery describes TROPION-Breast02 studying Dato-DXd in frontline patients with metastatic TNBC for patients ineligible for immunotherapy, similar to ASCENT-03 design but with important differences in eligibility criteria.
A key distinction involved disease-free interval requirements. TROPION-Breast02 included patients with early recurrences after neoadjuvant therapy, typically excluded from clinical trials due to concerns about aggressive disease biology. This inclusion represents important progress for patients experiencing rapid relapse after curative-intent treatment.
The trial enrolled potentially more aggressive disease cases and demonstrated significant improvements in both PFS and OS with frontline Dato-DXd, leading to recent FDA approval for this indication.
Dr. Iyengar highlights important trial design differences affecting interpretation, particularly regarding crossover patterns. ASCENT-03 and ASCENT-04 provided SG to control arm patients as second-line therapy, with over 80% crossover rates potentially confounding OS endpoints.
Response rate differences emerged between agents, with Dato-DXd achieving over 60% response rates in TROPION-Breast02 versus SG’s approximately 50% rates in ASCENT trials. Dr. Nunnery notes this might influence selection for patients requiring rapid responses due to heavy disease burden.
However, both agents demonstrated similar duration of response, questioning whether initial response rate differences translate into meaningful long-term clinical advantages. Patient-reported outcomes data provides reassuring evidence that ADCs offer better quality-of-life experiences compared to standard chemotherapy, supporting their use in frontline settings for appropriate patients.
